The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies.
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; AstraZeneca; Bayer; Bristol-Myers Squibb; G1 Therapeutics; Ipsen; Merck; Takeda
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Regeneron (Inst); Seagen (Inst); Symphogen (Inst); Takeda (Inst); Tesaro (Inst); United Therapeutics (Inst)
 
Amy Dickson
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
Patents, Royalties, Other Intellectual Property - Bicycle Therapeutics
 
Sandra Hirschberg
Employment - Bicycle Therapeutics; Ipsen
Stock and Other Ownership Interests - GlaxoSmithKline; Ipsen
 
Sally Westrup
Employment - Abbvie; Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
 
Punit Upadhyaya
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
Patents, Royalties, Other Intellectual Property - On multiple patents at Bicycle Therapeutics, Ra Pharmaceuticals (now UCB) and the Ohio State University
Travel, Accommodations, Expenses - Bicycle Therapeutics
 
Heather Cohen
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
Patents, Royalties, Other Intellectual Property - Bicycle Therapeutics
 
Kristen Hurov
Employment - Bicycle Therapeutics; Cygnal Therapeutics (I); Fog Pharmaceuticals (I)
Stock and Other Ownership Interests - Bicycle Therapeutics; Cygnal Therapeutics (I); Fog Pharmaceuticals (I); Novartis
Patents, Royalties, Other Intellectual Property - Bicycle Therapeutics
 
Roshawn Watson
Employment - Bicycle Therapeutics; Epizyme (I); KSQ Therapeutics (I); Vertex
Stock and Other Ownership Interests - Bicycle Therapeutics; Epizyme (I); KSQ Therapeutics (I); Vertex
Travel, Accommodations, Expenses - Vertex
 
Sebastien Hazard
Employment - Bicycle Therapeutics; GlaxoSmithKline; Tesaro
Stock and Other Ownership Interests - Bicycle Therapeutics; GlaxoSmithKline; ImmunoGen; Tesaro
 
Dominic Smethurst
Employment - Bicycle Therapeutics
Leadership - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Ellipses Pharma; iOnctura; Kelun Pharmaceuticals/Klus Pharma; Molecular Partners; Peptomyc
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social